Picture a primary care physician sitting across from a patient who has been on daily basal insulin for three years — injection fatigue written across the patient’s face, an HbA1c that refuses to budge, and a conversation about GLP-1s that the physician has already had twice. Now imagine handing that physician a pen that the patient only needs to use once a week. That is the commercial moment FDA’s approval of insulin icodec-abae, marketed as Awiqli, was designed to create — and Novo Nordisk has been engineering it for years.
The headline reads like an incremental advance: once-weekly basal insulin approved for adults with type 2 diabetes, the first of its kind. The street will treat it as a footnote to the GLP-1 story. That framing misses the strategic architecture entirely.
Novo Nordisk built Awiqli for a world in which GLP-1 adoption is simultaneously eating its insulin franchise and failing to reach every patient who needs it. According to CDC data from 2024, only 26.5% of adults with diagnosed diabetes in the United States — roughly 6.9 million people — used GLP-1 injectables. The remaining patient population still depends on insulin to manage glycemic control. Awiqli does not compete with semaglutide or tirzepatide. It competes for retention of the patients GLP-1s cannot fully serve, or have not yet reached.
The Adherence Arbitrage No One Is Pricing
Here is the counterintuitive read: the commercial case for once-weekly insulin is stronger precisely because daily basal insulin adherence is so poor. Most formulary committees and payer analysts will evaluate Awiqli on clinical differentiation — does it lower HbA1c more than daily insulin? The ONWARDS 3 trial data, published in JAMA and indexed in PubMed, showed superior HbA1c reduction for insulin-naive adults with type 2 diabetes compared to standard-of-care daily basal insulin. But that is the wrong question for the commercial team to be answering.
The right question is what happens to outcomes when a patient goes from seven injection events per week to one. Adherence is not a soft endpoint — it is a revenue driver and a total cost of care argument. Novo Nordisk’s BD team knows this. Payers are starting to know this. And the ADA’s 2024 Standards of Medical Care already position basal insulin initiation as a key intervention for patients whose HbA1c remains above target on oral agents — a population in the tens of millions globally.
The adherence arbitrage works like this: daily insulin patients who miss doses create downstream complications, hospitalizations, and poorly controlled A1c values that cost payers far more than the price differential between once-daily and once-weekly insulin. If Novo Nordisk can demonstrate — in real-world evidence post-launch — that once-weekly dosing translates to measurable adherence improvement and fewer acute care events, Awiqli becomes a formulary story about cost avoidance, not just a clinical story about HbA1c. That reframing is worth hundreds of millions in peak sales projections.
The $1.2 Billion Number Hiding in Plain Sight
Wall Street’s current read on Awiqli is cautiously optimistic and commercially modest. S&P Global forecasts Awiqli reaching approximately $174 million in 2026 revenue — up from $65 million in 2025 before US approval — climbing to $311 million by 2027, and reaching peak global sales of roughly $1.2 billion by 2034. Those numbers sound respectable until you compare them to the addressable population and realize how conservative the assumption about conversion rates must be.
A peak of $1.2 billion on a global basal insulin market that serves hundreds of millions of patients represents a penetration rate measured in single-digit percentages. That is not a ceiling built on clinical reality — it is a ceiling built on pricing assumptions and payer resistance that Novo Nordisk’s commercial team has every incentive to dismantle, one managed care contract at a time.
Eli Lilly is not standing still. The S&P Global analysis that projected Awiqli’s revenue trajectory also flagged Lilly as closing the gap in the once-weekly insulin race — a direct competitive threat to Novo Nordisk’s first-mover advantage. Lilly’s basal insulin pipeline is positioned to enter a market that Novo Nordisk will have spent two years conditioning for weekly dosing. First-mover advantage in pharmaceuticals is real, but it is measured in formulary positioning and prescriber habit — not approval dates. Novo Nordisk has roughly 18 to 24 months to convert the once-weekly concept into an entrenched clinical default before Lilly’s alternative arrives with a comparable clinical package and a promotional budget to match.
What the Boardroom Should Actually Be Doing
For Novo Nordisk’s commercial leadership, the risk calculus on Awiqli has shifted the moment the FDA approval letter arrived. The priority should not be physician detailing — primary care physicians already understand basal insulin. The priority is payer access architecture. Getting Awiqli onto Tier 2 of major PBM formularies before Lilly enters the space will define whether those $1.2 billion peak sales projections are a floor or a ceiling. Every quarter of preferred formulary status that Novo Nordisk locks in before a competitor arrives compounds into switching-cost protection.
Biotech CEOs watching from the outside should read Awiqli’s approval as evidence that lifecycle innovation in mature therapeutic categories still commands regulatory and commercial traction — if the innovation addresses a real patient behavior problem rather than a pharmacological one. Dosing frequency is not a trivial convenience claim. It is the mechanism by which real-world outcomes diverge from clinical trial outcomes, and the FDA’s willingness to approve Awiqli on the strength of a rigorous Phase 3 program signals that adherence-enabling design is a legitimate differentiation axis for future insulin and injectable drug development.
For BD teams at mid-cap diabetes companies, the immediate implication is competitive positioning review. Any asset in the basal insulin or long-acting injectable space that cannot articulate a dosing-frequency or convenience advantage against Awiqli now faces a structurally harder reimbursement argument. The bar has moved — and it moved on the day the FDA approved a once-weekly insulin, not the day a competitor launches one.
The hypoglycemia signal deserves a paragraph from the boardroom, too. Across three of the six ONWARDS trials, the incidence of combined Level 2 and Level 3 hypoglycemia was numerically higher with icodec than with comparator insulins. That finding will not stop launch — the overall profile supports approval and the FDA agreed — but it will shape the medical affairs narrative, the REMS-adjacent safety communication strategy, and the payer conversations about which patients are appropriate candidates. Endocrinologists will titrate carefully. Primary care physicians, who write the majority of basal insulin prescriptions, will need clear guidance on patient selection. How Novo Nordisk handles that safety communication in the first 12 months of launch will determine whether the hypoglycemia signal becomes a prescribing friction point or a manageable footnote.
Awiqli’s approval is ultimately a test of whether pharmaceutical innovation in a category dominated by GLP-1 narrative can still command commercial attention — and whether Novo Nordisk can convert a first-mover window into a durable franchise before Lilly closes the distance. The $1.2 billion peak sales estimate assumes it cannot. Novo Nordisk’s entire launch strategy should be built around proving that assumption wrong before 2028.
References
- JAMA — “FDA Approves Weekly Basal Insulin for Adults With Type 2 Diabetes”
- PubMed — ONWARDS 3 Trial: Insulin icodec vs. daily basal insulin in insulin-naive adults with type 2 diabetes
- CDC National Center for Health Statistics — GLP-1 Injectable Use Among U.S. Adults with Diagnosed Diabetes, 2024
- American Diabetes Association — Standards of Medical Care in Diabetes 2024: Pharmacologic Approaches to Glycemic Treatment
- S&P Global Market Intelligence — “Novo Nordisk Secures US Lead in Once-Weekly Insulin Race, But Lilly Seen Closing Gap”
- Clinical Trials and Clinical Research — Hypoglycemia Safety Profile Review of ONWARDS Trials
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
